Sponsors keep asking one stacked question: how do I obtain ANVISA, COFEPRIS, ANMAT, or Panama MINSA approval for a medical device clinical trial? Those four names are not interchangeable stamps. Each one is a different investigation desk, with a different ethics gate, and a different investigational-import story. Treating them as one “LATAM approval” is how a Gantt goes soft.
I am Julio Martinez-Clark, CEO of bioaccess®. This page is a comparison hub for medical-device clinical-investigation authorization in Brazil, Mexico, Argentina, and Panama. It is grounded in live bioaccessla.com posts on the FIH startup clock, investigational import, ANMAT investigation checklist, Mexico’s COFEPRIS reset, and the Panama / El Salvador corridor pages. It is not a quote and not legal advice. Confirm every instrument against each agency’s current published texts before you file.
Write four columns before translators start
Put these four tracks on one page. Do not merge them into a single “regulatory” bar.
- Brazil — ANVISA. Agency review of the device clinical investigation, plus ethics (CEP/CONEP), plus a two-layer import path.
- Mexico — COFEPRIS. Federal protocol authorization, plus CONBIOÉTICA-linked ethics, plus a research-use import permit.
- Argentina — ANMAT. Investigation authorization (not commercial registro), plus independent ethics, plus provincial filings where required.
- Panama — MINSA. Ministry of Health investigation track with CNBI-registered ethics — the documented sprinter in the fast corridor.
If the board slide says “we got LATAM approval,” ask which desk, which ethics letter, and which import document.
Same question, four different clocks
Published operator planning bands on the live startup clock (confirm at contracting):
| Country / desk | Planning activation band | Why the band looks that way |
|---|---|---|
| Panama — MINSA + CNBI ethics | 15–45 days (fast corridor) | Ethics-submission ID in about 3 business days on published experience; parallel ethics and regulator work; about 15-day activation achieved in a real program |
| Mexico — COFEPRIS + ethics | Historically 6–9 months; watchlist with asterisk | Published reset language cuts protocol review toward ~30 days with ethics ~4–6 weeks in parallel — verify measured clocks before you put Mexico in the fast corridor by default |
| Brazil — ANVISA + CEP/CONEP | 6–9 months | Full agency review plus ethics; largest patient pool in the region |
| Argentina — ANMAT + ethics | 6–9 months | Investigation desk with a 90-business-day statutory review target that pauses for RFIs; FIH/EFS often exceeds the target |
Panama sits with Chile, El Salvador, and Costa Rica in the 15–45 day corridor. Mexico, Brazil, Colombia, and Argentina sit in the major-market band unless a measured clock proves otherwise.
Brazil — ANVISA (investigation + import are two layers)
For investigational devices, Brazil is a two-layer system on the live import guide:
- ANVISA clinical-investigation approval under RDC 837/2023. The Comunicado Especial lists the investigational products and authorized quantities.
- Licença de Importação (LI) in Siscomex with ANVISA release at the port. The import rulebook (RDC 81/2008) is under revision — confirm the current instrument before citing it at filing.
Ethics runs through CEP/CONEP. Portuguese certificate-of-insurance language is not optional stationery for that packet. Use the Brazil clinical-trials hub for clocks; do not invent medians here.
Operator check: freeze the investigational product list once. The Comunicado Especial quantities must match what Siscomex will see. A commercial sanitary registration number does not clear FIH freight.
Mexico — COFEPRIS (reset language ≠ measured clock yet)
COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico’s federal health regulator. CONBIOÉTICA is the national bioethics commission. Live COFEPRIS reset coverage already states:
- Published direction cuts clinical-trial protocol review from ~120 days toward ~30 days.
- An abbreviated pathway in force since 1 September 2025 gives ~30-business-day device decisions for products already authorized by certain reference regulators.
- A 15 January 2026 decree amended the Ley General de Salud on clinical-research reform, with COFEPRIS–CONBIOÉTICA coordination.
- Regulatory reliance language recognizes evaluations by FDA, EMA, MHRA, and Health Canada for clinical-research protocols.
- Ethics / IRB review remains a separate ~4–6 week benchmark clock.
Import: a research-use import permit connected to the COFEPRIS trial authorization. Confirm the current COFEPRIS procedure at filing — agency processes have been changing.
Until sponsors and CROs have measured real-world clocks across several submissions, keep Mexico on the watchlist with an asterisk. Parallelize ethics and regulator filings; do not bank the announcement as Panama-class speed.
Argentina — ANMAT (investigation is not registro)
ANMAT is one agency name on two files. Write them apart before anyone translates:
- Investigation file. Clinical-investigation authorization for FIH or early feasibility, plus independent ethics under ISO 14155 and the Declaration of Helsinki, plus provincial oversight where required (for example Buenos Aires). Disposición ANMAT 7516/2025 Article 5 assigns clinical-investigation evaluation to the Dirección de Investigación Clínica. Published planning framework: 90-business-day statutory review target that pauses for RFIs.
- Registro file. Sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including HELENA declaración jurada routes for eligible CE-marked Class I/II. Success criterion: a selling license — not a trial letter.
Import authorization links to the ANMAT trial approval through a licensed importer of record. Argentina’s import documentation is exacting. Reconcile every document before filing. A HELENA DDJJ or a cousin SKU’s registro does not move investigational kits.
Full dossier checklist: see the live ANMAT clinical-trial submission checklist.
Panama — MINSA (fast corridor, still two files)
Panama’s Ministry of Health (MINSA) oversees clinical investigations through the Dirección Nacional de Farmacia y Drogas on the live Panama hub language. Ethics review runs through institutional bioethics committees registered with the national CNBI. Published ethics band: about 3–5 weeks. Insurance exhibits belong in that packet.
Published Class III FIH geography language points at Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 on the Panama Class III FIH guide — confirm those instruments at filing. Dollarized economy, English-capable sites, investigation units only.
Import authorization is tied to the MINSA trial authorization. Panama’s fast startup clock only holds if import runs in parallel with ethics and regulatory submissions. Commercial registro stays a separate MINSA market-access file.
Universal dossier core (assemble once)
Use the same core across all four desks, then layer country packets. Grounded in the live LATAM FIH submission-package checklist:
| Section | Freeze once | Country layer |
|---|---|---|
| Protocol | Version, endpoints, stopping rules | Same version across agency + ethics packs |
| Investigator’s brochure / preclinical | Risk profile for first human use | Matches the article on the investigational list |
| Informed consent | Local language for ethics | Spanish (MX/AR/PA) or Portuguese (BR) — not the later commercial IFU |
| Insurance | Trial-related injury coverage | Territory and named parties match the sites |
| ISO 14155 monitoring plan | GCP bridge for foreign data | Design for 21 CFR § 812.28 inspectability if a U.S. file is intended |
| Investigational labeling + device list | Lot/serial accountability | Quantities match what import will request (BR: Comunicado Especial) |
| Importer of record | Legal name before ethics stamps | Document ties shipment to investigation authorization |
How these approvals relate to FDA
A clean ANVISA, COFEPRIS, ANMAT, or MINSA investigation letter does not replace an inspectable trial master file. Foreign clinical data can be eligible for FDA submission and review under 21 CFR § 812.28 when the investigation meets the GCP conditions in that rule. ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. Eligibility is not a clearance prediction. Keep device accountability, deviation logs, monitoring reports, and ethics correspondence in one place from day one. See the live FDA 21 CFR 812.28 LATAM inspectability and FDA acceptance of LATAM FIH data pages.
Common failure patterns across all four
- One LATAM Gantt bar. Panama’s corridor clock does not transfer to ANVISA or ANMAT.
- Registro number on investigational freight. Commercial certificates do not clear FIH kits in Brazil, Mexico, Argentina, or Panama.
- Ethics after agency. Sequential filing burns calendar the statutory targets never promised to absorb.
- Importer named after first patient. Import then becomes the critical path ethics cannot fix.
- Announcement clocks treated as measured clocks. Especially Mexico’s COFEPRIS reset — verify before you promise the board.
One-page gate before first patient
- Country shortlist with indication-level patient flow — not just the fastest desk.
- Authority map: investigation desk + ethics (+ provincial / CONEP / CNBI as applicable) versus commercial registro on a separate track.
- Same protocol version across every packet.
- Importer named, with the document that ties shipment to investigation authorization.
- Device list complete, including accessories and authorized quantities.
- ISO 14155 file owner who can produce monitoring, accountability, and ethics letters within 48 hours if FDA asks.
Related reading on bioaccessla.com
- How long does it take to start a FIH trial in Latin America?
- Importing investigational devices into Latin America
- ANMAT clinical-trial submission checklist
- ANMAT trial authorization vs registro
- Mexico’s COFEPRIS reset for FIH sponsors
- Panama or El Salvador FIH cost vs the US
- Clinical trial insurance in Latin America
- Universal LATAM FIH submission package
- Medical device registration & market access
Planning a multi-country FIH file across Brazil, Mexico, Argentina, or Panama? Talk with bioaccess® about sequencing investigation desks, ethics, and investigational import — contact Julio Martinez-Clark at jmclark@bioaccessla.com or +1 (954) 903-7210.